Alcohol Clin Exp Res
March 1, 2026
Sarah D Jennings, Ian Yates, Samantha K Saland et al.
Background: Effective pharmacotherapies for Alcohol Use Disorder (AUD) are lacking, and factors such as sex, drinking patterns, and timing of treatment during the addiction cycle may influence treatment efficacy. Clinical studies suggest that ketamine may be effective in AUD; however, preclinical findings have been inconclusive, likely due to varying rodent strains, intake protocols, and...
International Journal of Psychiatry in Clinical Practice
March 2026
Guoguang Song, Ugwah-Oguejiofor Chinenye Jane
Electroconvulsive therapy (ECT) has long been considered the main method of treatment for patients with resistant major depressive disorder (MDD). Recent studies have shown that ketamine infusion can also effectively improve treatment-resistant MDD. Thus, we conducted this meta-analysis to compare the efficacy of ketamine with ECT for treating treatment-resistant depression. We systematically...
Journal of Palliative Medicine
March 1, 2026
Robert K Horowitz, William E Rosa, Ali John Zarrabi et al.
Psychospiritual distress (PSD) causes profound suffering in people with serious illness, yet treatment options are few and evidence of their efficacy is modest. Although high-level evidence is limited, decades of preliminary research suggest that psychedelic-assisted psychotherapy (PAP), including ketamine-assisted psychotherapy (KAP), may alleviate the anxiety, depression, and existential...
Psychiatry Research
March 1, 2026
Gijsbrecht H. J. Roelandt, Jurriaan F M Strous, Radboud M Marijnissen et al.
1 citation
Ketamine has been shown to decrease suicidality in patients with depression. However, little is known about tolerability and efficacy in heterogenous, acutely suicidal patients in emergency settings. This pilot study aimed to assess the feasibility, acceptability, and safety of generic intranasal racemic ketamine (75 mg) in the treatment of acute suicidality regardless of the underlying...
Biological Psychiatry Global Open Science
March 1, 2026
Noam Goldway, Taly Markovits, Naomi Fine et al.
1 citation
Dissociation, an altered state of consciousness in which individuals feel detached from their body, environment, and sense of self, is a common feature of posttraumatic stress disorder (PTSD). Despite its significance, the neurocognitive processes underlying dissociation remain poorly understood, potentially limiting diagnostic precision and treatment efficacy in PTSD. To address this gap, we...
BMJ Open
March 1, 2026
Christina Mcanulty, Philippe Lavoie, Samuel Cyr et al.
BACKGROUND: Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid antidepressant effects and has shown promise in reducing alcohol use, and acceptance and commitment therapy (ACT) can be effective for both substance use and mood disorders. This study explores the...
WSQ: Women's Studies Quarterly
March 1, 2026
Susan Merrill Squier
Abstract: After an episode of painful ovarian torsion, I accepted a surgeon's counsel to undergo a hysterectomy/oophorectomy at the age of forty-six. The sudden menopause this surgery brought on intensified a chronic depression. Several decades later, after undergoing ketamine infusion treatments for my depression, I recognized that surgery as an experience of iatrogenic harm, part of the...
The Nursing clinics of North America
March 1, 2026
Amanda Canada
Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) often co-occur, worsening outcomes, relapse rates, and treatment response. Ketamine produces rapid and sustained PTSD symptom reduction and reduces AUD relapse. Prazosin effectively treats PTSD-related nightmares and may reduce alcohol consumption in individuals with heightened autonomic reactivity. The dual complementary...
Zenodo (CERN European Organization for Nuclear Research)
February 28, 2026
Kshirsagar Pankaj*, Misal Shivdarshan, Dr. Giri Ashok
preprint
Major Depressive Disorder (MDD) and Bipolar Depression represent significant global health burdens because about one-third of patients who receive standard monoaminergic antidepressant treatment fail to achieve remission. The population with Treatment-Resistant Depression (TRD) needs assistance because they deal with dangerous suicide risks and struggle with their daily activities. The review...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
February 27, 2026
Chris H. Miller, Angela Hickman, Caitlin Baten et al.
2 citations
Ketamine pharmacotherapy provides a novel treatment option for major depressive disorder (MDD) and has generated a large, growing body of research regarding its biochemical and clinical properties. This narrative review summarizes the history of ketamine's development, beginning as a general anesthetic, continuing with a discovery of its antidepressant properties, and leading up to its landmark...